Proactive Investors - Run By Investors For Investors

Zelda Therapeutics to outline cannabinoid-based strategy at Proactive CEO Sessions

The company was recently awarded a patent for a novel prognostic biomarker for breast cancer.
Zelda managing director Dr Richard Hopkins
Zelda managing director Dr Richard Hopkins

Zelda Therapeutics Ltd (ASX:ZLD) is developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions, with a focus on cancer therapies.

The company is undertaking:

• A human clinical trial program focused on insomnia, autism and opioid reduction with activities in Australia and the USA.

• A pre-clinical research program examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Zelda managing director Dr Richard Hopkins will present to investors at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.

Range of commercialisation opportunities

Zelda’s recent developments include a heads of agreement (HoA) with medicinal cannabis company Ilera Healthcare to explore collaborative opportunities and being granted a new patent covering a novel method to predict patient disease-free survival.

The range of commercialisation opportunities with US-based Ilera include licensing of Zelda products, co-development and data sharing.

READ: Zelda Therapeutics secures patent to detect breast cancer

Zelda’s Australian patent details a method for detecting levels of expression of a novel receptor complex containing proteins HER2 and CB2.

HER2 is a recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system.

Register for the CEO Sessions today

Sydney details, Monday, May 13, 2019

Melbourne details, Tuesday, May 14, 2019

Also featuring at both sessions will be Xanadu Mines Ltd (ASX:XAM), Infinity Lithium Ltd (ASX:INF), Oventus Medical Ltd (ASX:OVN and Invitrocue Ltd (ASX:IVQ).

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

cannabis flower
April 26 2019
The company's footprint continues to grow as it focuses on becoming a globally recognized house of brands with a broad portfolio of clients across North America
medical cannabis concept
February 10 2019
AusCann is a fully integrated early-mover pharmaceutical cannabinoid company.
FSD Pharma facility
Tue
The indoor hydroponic facility will be optimized for large-scale, medical-grade cannabis production and once complete, is expected to have over 3.9 million sq/ft available for production

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use